OBJECTIVES: V116 is a 21-valent pneumococcal conjugate vaccine (PCV) specifically designed for adults. It includes 8 unique serotypes (15A, 15C [from deOAc-15B], 16F, 23A, 23B, 24F, 31 and 35B) not covered by any currently licensed pneumococcal vaccine. According to published data in 2022, the serotypes covered by V116 are responsible for approximately 75.9% of invasive pneumococcal disease (IPD) in individuals aged 60+ years in Greece, and the unique 8 serotypes were responsible for approximately 26.4%. This study estimates the potential health and economic impact of vaccination with V116 vs. PCV20 on IPD in adults aged 19+ years in Greece.

METHODS: A Markov model was built to estimate the lifetime IPD cases, IPD related deaths, and the associated direct and indirect medical costs among the adults aged 19-64 with risk conditions and 65+ vaccinating with V116 or PCV20. The same serotype specific vaccine effectiveness, and the same vaccine coverage rates (40%) were assumed for the two vaccines.

RESULTS: In adults aged 19-64 with risk conditions, compared to no vaccination, V116 prevented 752 IPD cases and 82 IPD deaths – 45% more than the 520 IPD cases and 57 IPD deaths prevented by PCV20. The averted IPD cases by V116 saved €1.64 million in total medical costs – 45% higher than the €1.13 million costs averted by PCV20.

In adults aged 65+, compared to no vaccination, V116 prevented 794 IPD cases and 124 IPD deaths – 45% more than the 549 IPD cases and 86 IPD deaths prevented by PCV20. The averted IPD cases by V116 saved €1.78 million in total medical costs – 45% higher than the €1.23 million costs averted by PCV20.

CONCLUSIONS: In both age groups, comparing with PCV20, V116 led to a greater reduction of both the health and economic burden associated with IPD in Greece.